Private company

DYNATRONICS CORP

Leading medical device company1

In its 2025 annual report the company says: “The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin, Solaris, Hausmann, PROTEAM, and Mammoth, among others.”4 It is headquartered in Salt Lake City, Utah.1

Last updated Oct 21, 2026.

Overview

$27.4MRevenue, fiscal 20252
-$10.9MNet income, fiscal 20252
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSalt Lake City, Utah1
  • Incorporated inUT3
  • Business address7030 Park Centre Drive, Bldg D, Salt Lake City, Ut 841213
  • Filer categoryNon-accelerated filer, Smaller reporting company3

Dynatronics Corporation is a leading medical device company committed to providing high-quality products designed to accelerate optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin, Solaris, Hausmann, PROTEAM, and Mammoth, among others.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

21.9%Gross margin2
-9.0%Operating margin2
-39.8%Net margin2
-15.8%Revenue growth, 20252
-334.2%Return on equity2
$270.1KFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue71¢$21.4M
  • Selling, general and admin28¢$8.5M
  • Interest1¢$409.9K
  • Income tax0¢$12.2K

Out of $27.4M in revenue.2 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending10¢$30.4K
  • Kept or used elsewhere90¢$270.1K

Out of $300.6K of cash from operations.2

Financial statements

Revenue56789102$27.4M in 2025−57% since 2018
0$20.0M$40.0M$60.0M$80.0M2018: $64.4M$64.4M20182019: $62.6M$62.6M2019−3%2020: $53.4M$53.4M2020−15%2021: $47.8M$47.8M2021−11%2022: $44.3M$44.3M2022−7%2023: $40.6M$40.6M2023−8%2024: $32.5M$32.5M2024−20%2025: $27.4M$27.4M2025−16%
Gross profit56789102$6.0M in 2025−71% since 2018
0$10.0M$20.0M$30.0M2018: $20.4M$20.4M20182019: $19.2M$19.2M2019−6%2020: $15.1M$15.1M2020−21%2021: $12.9M$12.9M2021−15%2022: $10.7M$10.7M2022−17%2023: $10.2M$10.2M2023−5%2024: $7.6M$7.6M2024−25%2025: $6.0M$6.0M2025−21%
Operating income56789102-$2.5M in 2025+96% since 2018
-$6.0M-$4.0M-$2.0M02018: -$1.3M-$1.3M20182019: -$796.1K-$796.1K2019−36%2020: -$3.0M-$3.0M2020+276%2021: -$3.8M-$3.8M2021+26%2022: -$4.8M-$4.8M2022+26%2023: -$4.9M-$4.9M2023+2%2024: -$2.3M-$2.3M2024−53%2025: -$2.5M-$2.5M2025+8%
Net income56789102-$10.9M in 2025+580% since 2018
-$15.0M-$10.0M-$5.0M0$5.0M2018: -$1.6M-$1.6M20182019: -$921.7K-$921.7K2019−42%2020: -$3.4M-$3.4M2020+272%2021: $2.0M$2.0M20212022: -$4.0M-$4.0M20222023: -$5.0M-$5.0M2023+25%2024: -$2.7M-$2.7M2024−46%2025: -$10.9M-$10.9M2025+304%
Fiscal year20182019202020212022202320242025
Revenue$64.4M5$62.6M6$53.4M7$47.8M8$44.3M9$40.6M10$32.5M2$27.4M2
Cost of revenue$44.0M5$43.4M6$38.3M7$34.9M8$33.7M9$30.5M10$24.9M2$21.4M2
Gross profit$20.4M5$19.2M6$15.1M7$12.9M8$10.7M9$10.2M10$7.6M2$6.0M2
Research and development$1.2M13$54.0K6$95.0K7$10.0K7
Selling, general and admin$21.7M5$20.0M6$18.1M7$16.6M8$15.4M9$15.0M10$9.9M2$8.5M2
Operating income-$1.3M5-$796.1K6-$3.0M7-$3.8M8-$4.8M9-$4.9M10-$2.3M2-$2.5M2
Interest-$428.5K5$512.2K6$435.6K7$215.6K8$148.0K9$118.3K10$418.0K2$409.9K2
Income before tax-$4.0M9-$5.0M10-$2.7M2-$10.9M2
Income tax$70.3K5$5.5K6-$10.1K7$10.0K8$09$010$02$12.2K2
Net income-$1.6M5-$921.7K6-$3.4M7$2.0M8-$4.0M9-$5.0M10-$2.7M2-$10.9M2
Earnings per share-$1.329-$1.4610-$1.002-$1.432
Earnings per share (diluted)-$1.329-$1.4610-$1.002-$1.432
Shares (weighted, basic)3.6M shares93.9M shares103.4M shares28.1M shares2
Shares (weighted, diluted)3.6M shares93.9M shares103.4M shares28.1M shares2

Compare DYNATRONICS CORP with another company

Corporate structure

DYNATRONICS CORP sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of DYNATRONICS CORP

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on DYNATRONICS CORP, latest Feb 17, 2026 (4 filings since Feb 15, 2022)
  • RENAISSANCE TECHNOLOGIES LLC Filed SC 13G/A on DYNATRONICS CORP, latest Feb 13, 2023 (2 filings since Feb 11, 2022)
  • Nancy Cronin Filed SC 13G/A on DYNATRONICS CORP, latest Jan 14, 2022
  • DYNATRONICS CORP Salt Lake City, Utah

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What DYNATRONICS CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$6.8M2 Jun 30, 2025$7.4M2 Jun 30, 2024−7.7%
Accumulated depreciation$5.3M2 Jun 30, 2025$5.4M2 Jun 30, 2024−2.2%
Property and equipment, net$1.5M2 Jun 30, 2025$2.0M2 Jun 30, 2024−23.1%
Operating-lease assets (leased space)$3.2M2 Jun 30, 2025$2.8M2 Jun 30, 2024+12.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$326.3K2 Jun 30, 2025$483.9K2 Jun 30, 2024−32.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$02 Jun 30, 2025$7.1M2 Jun 30, 2024−100.0%
Intangible assets, net (excluding goodwill)$1.4M2 Jun 30, 2025$3.0M2 Jun 30, 2024−52.3%
Indefinite-lived intangibles (excluding goodwill)$4.5M2 Jun 30, 2025$7.7M2 Jun 30, 2024−41.4%
Accumulated amortization$3.1M2 Jun 30, 2025$4.7M2 Jun 30, 2024−34.5%
Finite-lived intangibles, net$873.4K2 Jun 30, 2025$1.9M10 Jun 30, 2024−54.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$5.1M2 Jun 30, 2025$5.6M2 Jun 30, 2024−9.3%
Raw materials$3.3M2 Jun 30, 2025$3.6M2 Jun 30, 2024−9.3%
Work in process$351.5K2 Jun 30, 2025$315.1K2 Jun 30, 2024+11.6%
Finished goods$2.0M2 Jun 30, 2025$2.3M2 Jun 30, 2024−11.3%

Properties, in its own words

We lease a 57,000 square-foot manufacturing, warehouse, and office facility in Eagan, Minnesota, which houses our corporate headquarters and principal executive offices. Lease payments are $40,000 per month. The original term of the lease is for thirty nine months, commencing in April 2025. The lease is subject to 4% increases each subsequent year. The lease also includes a renewal option for an additional 36 months at Market Rate. We believe that the terms of the agreement are commercially reasonable for the market in which the facility is located.

We lease a 60,000 square-foot manufacturing and office facility in Northvale, New Jersey to house our Hausmann Enterprises, LLC operations. The initial two-year term of this lease commenced in April 2017, with monthly lease payments of $30,000 for the first year and 2% increases in each subsequent year. The lease provides for two options to extend the term of the lease for two years per extension term, subject to annual 2% per year increases in base rent, and a third extension option at the end of the second option term for an additional five years at fair market value. We have exercised options to extend the term of the lease through March 2028, with monthly lease payments of $60,000 for the first year, 2% increases each subsequent year, and monthly solar payments that total approximately $9,000 per year starting July 2023. The landlord is a stockholder and the previous owner of the assets and operations acquired in 2017. The lease was negotiated at arms' length as part of the Hausmann acquisition. We believe that the terms of the agreement are commercially reasonable for the market in which the facility is located.

The rest of Item 2

We lease a 36,000 square-foot manufacturing, warehouse, and office facility in Cottonwood Heights, Utah. We sold the building in August 2014, and now lease it back from the purchaser. The monthly lease payment is approximately $32,000 and the lease terminates in 2029. We account for the lease-back agreement as a finance lease which results in depreciation and implied interest expense each period, offset by an amortized gain on the sale of the property. Overall the net monthly occupancy cost of this lease is $40,000.

We believe the facilities described above are adequate for our current needs and that they will accommodate our presently expected growth and operating needs. As our business continues to grow, additional facilities or the expansion of existing facilities may be required.

We also own computer equipment, and equipment used in the manufacture and assembly of our products. The nature of this equipment is not specialized and replacements may be readily obtained from any of a number of suppliers.

Item 2 of the 10-K filed Oct 14, 2025.4

Leadership

Who has led DYNATRONICS CORP, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (26)

Timeline

  1. Jan 12, 20268-K Bankruptcy or receivership; Debt or obligation accelerated; Executive or director change47
  2. Dec 17, 20258-K Shareholder vote48
  3. May 9, 20258-K Executive or director change49
  4. Apr 18, 20258-K Executive or director change50
  5. Apr 4, 20258-K Entered a material agreement51
  6. Dec 9, 20248-K Shareholder vote52
  7. Sep 24, 20248-K Executive or director change53
  8. Jun 28, 20248-K Listing notice or transfer; Regulation FD disclosure54
  9. May 16, 20248-K Results of operations55
  10. Apr 29, 20248-K Listing notice or transfer56
  11. Mar 20, 20248-K Executive or director change57
  12. Feb 8, 20248-K Results of operations58
  13. Jul 21, 2020New chief executive John Anthony Krier becomes CEO14
  14. Jun 27, 2018New chief executive Jako Christopher Richard Von becomes CEO15
  15. Jan 4, 2007New chief executive Kelvyn H. Cullimore Jr. becomes CEO16

Calendar

When it reported results

  1. May 16, 2024Reported quarterly or annual results55
  2. Feb 8, 2024Reported quarterly or annual results58
  3. Nov 9, 2023Reported quarterly or annual results59
  4. Sep 28, 2023Reported quarterly or annual results60
  5. May 11, 2023Reported quarterly or annual results61
  6. Feb 9, 2023Reported quarterly or annual results62
  7. Nov 10, 2022Reported quarterly or annual results63
  8. Sep 22, 2022Reported quarterly or annual results64

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

210 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 44 major events, 126 insider forms, 7 large holders, 16 other. The latest 20:

  1. Feb 17, 2026SCHEDULE 13G/A EDGAR
  2. Jan 12, 20268-K EDGAR
  3. Dec 17, 20258-K EDGAR
  4. Nov 19, 202510-Q EDGAR
  5. Nov 17, 2025NT 10-Q EDGAR
  6. Oct 30, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  7. Oct 30, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  8. Oct 30, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  9. Oct 30, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  10. Oct 28, 2025ARS EDGAR
  11. Oct 28, 2025DEFA14A EDGAR
  12. Oct 28, 2025DEF 14A EDGAR
  13. Oct 23, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  14. Oct 15, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  15. Oct 15, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  16. Oct 15, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  17. Oct 15, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  18. Oct 14, 202510-K EDGAR
  19. Oct 3, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Oct 3, 20254 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 210 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 13 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 4, 2022Ward R ScottDirectorBuy5,000Form 4
Jan 4, 2022Provco Ventures 1 LP10% ownerBuy37,552Form 4
Jan 4, 2022LARKIN BRIANDirectorBuy3,734Form 4
Jan 4, 2022KLOSTERMAN SCOTTDirectorBuy5,000Form 4
Jan 4, 2022HOLTZ DAVID BDirectorBuy5,000Form 4
Jan 4, 2022ESSIG STUART10% ownerBuy80,146Form 4
Jan 4, 2022ENRIGHT ERIN S.DirectorBuy80,146Form 4
Jan 4, 2022Baker Brian D.President & CEO, CFOBuy8,734Form 4
Oct 4, 2021Provco Ventures 1 LP10% ownerBuy26,155Form 4
Oct 4, 2021LARKIN BRIANDirectorBuy2,601Form 4
Oct 4, 2021ESSIG STUART10% ownerBuy52,338Form 4
Oct 4, 2021ENRIGHT ERIN S.DirectorBuy52,338Form 4
Oct 4, 2021Baker Brian D.President & CEO, CFOBuy3,671Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Brian D. Baker59$200.1K$213.4K68
2025Gabe Ellwein$180.7K$200.9K68
2025Ryan Staats46$23.1K$25.7K68
2024PresidentChief Executive Officer and Chief Financial Officer$248.6K$282.3K68
2024Former Chief Financial Officer$158.7K$169.2K68
2024Former ChiefExecutive and Financial Officer$66.5K$112.2K68

SEC filer profile

How DYNATRONICS CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDYNATRONICS CORP1
  • CIK0000720875
  • Employer ID (EIN)87-03984344
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inUtah4
  • Fiscal year endsJune 301
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address7030 Park Centre Drive, Bldg D, Salt Lake City, UT 841211
  • Mailing address7030 Park Center Dr, Salt Lake City, UT 841211
  • Phone80156870001
  • Shares outstanding16,048,734 as of Nov 12, 202512
  • Public float$600.0K as of Dec 31, 20244
  • AuditorTanner LLC, Salt Lake City, Utah PCAOB ID 270; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 18, 19951
  • Filings907 in all: 4 (382), 8-K (182), 10-Q (57), 10QSB (35), DEF 14A (31), 3 (30), 10-K (18), 4/A (17)1
    All 42 form types

    10KSB (12), ARS (10), 5 (9), UPLOAD (9), CORRESP (8), SC 13G/A (8), EFFECT (7), PRE 14A (7), S-3 (7), S-3/A (7), SC 13D/A (7), SC 13G (7), 10-K/A (6), 10-Q/A (6), REGDEX (6), D (5), S-8 (5), 8-K/A (4), 424B5 (3), DEFA14A (3), SC 13D (3), 10KSB/A (2), D/A (2), NT 10-Q (2), 10-K405 (1), 25-NSE (1), 5/A (1), DEFR14A (1), NT 10-K (1), PREM14A (1), PRER14A (1), S-8 POS (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Oct 14, 2025
    Quarterly report (10-Q) Nov 19, 2025
    Proxy statement (DEF 14A) Oct 28, 2025
    Latest 8-K (8-K) Jan 12, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock

From the cover page of the 10-K filed Oct 14, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks DYNATRONICS CORP names in Item 1A of its 10-K filed Oct 14, 2025: 39 risks under these headings, as written.4

  • Substantial Doubt About Our Ability to Continue as a Going Concern
  • Risks Related to Our Business and Industry
  • We expect to rely on third-party manufacturers and will be dependent on their quality and effectiveness.
  • Disruption of our supply chain could have an adverse impact on our business, financial condition, and results of operations.
  • Inflation and price fluctuations of raw materials, energy and other inputs could adversely affect our business.
  • We are currently operating in a period of economic uncertainty, which has been significantly impacted by geopolitical instability due to the ongoing conflicts in Ukraine and in the Middle East and heightened tensions resulting from recent attacks on shipping vessels in the Red Sea.
  • Any current or future outbreak of a health epidemic or other adverse public health developments could disrupt our manufacturing and supply chain, and adversely affect our business and operating results.
  • We have a history of losses, and we may not sustain profitability in the future.
  • We have incurred and may in the future incur non-cash impairment charges.
  • We may need additional funding and may be unable to raise additional capital when needed, which could adversely affect our results of operations and financial condition.
  • Our inability to successfully manage growth through acquisitions, and the integration of acquired businesses, products or technologies may present significant challenges and could harm our operating results.
  • If we fail to establish new sales and distribution relationships or maintain our existing relationships, or if our third party distributors and dealers fail to commit sufficient time and effort or are otherwise ineffective in selling our products, our results of operations and future growth could be adversely impacted.
The other 28 risks
  • Our products are regulated by numerous government agencies, both inside and outside the United States.
  • Changing market patterns may affect demand for our products.
  • The cost of healthcare has risen significantly over the past decade and numerous initiatives and reforms initiated by legislators, regulators and third-party payers to curb these costs have resulted in a consolidation trend in the restorative products industry as well as among our customers, including healthcare providers.
  • The sale, marketing, and pricing of our products, and relationships with healthcare providers are under increased scrutiny by federal, state, and foreign government agencies.
  • Our commercial activities internationally are subject to special risks associated with doing business in environments and jurisdictions that present a heightened corruption and trade sanctions risk.
  • If we fail to obtain regulatory approval in foreign jurisdictions, then we cannot market our products in those jurisdictions.
  • We store, process, and use data, some of which contain personal information and are subject to complex and evolving laws and regulations regarding privacy, data protection and other matters, which are subject to change.
  • Market access could be a limiting factor in our growth.
  • A significant percentage of our workforce is subject to a collective bargaining agreement.
  • We rely on a combination of patents, trade secrets, and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so.
  • Certain of the products we sell are subject to market and technological obsolescence.
  • We may be adversely affected by product liability claims, unfavorable court decisions or legal settlements.
  • Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.
  • Covenants in our loan documents may restrict our business and operations and if we cannot satisfy our covenants, our financial condition and results of operations could be adversely affected.
  • We operate in a highly competitive market segment, face competition from large, well-established medical device companies with significant resources, and may not be able to compete effectively.
  • We are dependent on our senior management team, sales and marketing team, engineering team and other qualified personnel, and the loss of any of them could harm our business.
  • Failures in, material damage to, or interruptions in our information technology systems, software or websites, including as a result of cyber-attacks, and difficulties in updating our existing software or developing or implementing new software, could have a material adverse effect on our business or results of operations.
  • Risks Related to Our Common Stock
  • A decline in the price of our common stock could affect our ability to raise working capital and adversely impact our operations.
  • Our stock price has been volatile and we expect that it will continue to be volatile.
  • Investors in our securities may experience substantial dilution upon the conversion of preferred stock to common, exercise of stock options and warrants, future issuances of stock, grants of restricted stock and the issuance of stock in connection with acquisitions of other companies.
  • The stock markets (including the OTC Venture Market, on which our common stock is traded) have experienced significant price and volume fluctuations.
  • We are able to issue shares of preferred stock with greater rights and preferences than our common stock.
  • The concentration or potential concentration of equity ownership by Prettybrook Partners, LLC and its affiliates may limit your ability to influence corporate matters.
  • Sales of a large number of our securities, or the perception that such sales might occur, could depress the market price of our common stock.
  • Our ability to issue preferred stock could delay or prevent takeover attempts.
  • As of the open of business on July 9, 2024, our common stock ceased trading on the NASDAQ Capital Market and began trading on the OTCQB Venture Market (the "OTCQB").
  • In addition to the foregoing, the application of the "penny stock" rules could adversely affect the market price of our common stock and increase the transaction costs to sell those shares.
  • We may pursue certain strategies that result in the deregistration of our common stock under the Exchange Act, which could negatively affect the liquidity and trading prices of our common stock and would result in less disclosure about the Company.

Legal proceedings

There are no pending legal proceedings of a material nature to which we are a party or to which any of our property is the subject.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68